Portland State University

PDXScholar
Dissertations and Theses

Dissertations and Theses

Winter 1-31-2017

Novel Compound, 84F2, Inhibits Calmodulin
Deficient RyR2
Robert Carl Klipp
Portland State University

Follow this and additional works at: https://pdxscholar.library.pdx.edu/open_access_etds
Part of the Cardiology Commons, and the Physics Commons

Let us know how access to this document benefits you.
Recommended Citation
Klipp, Robert Carl, "Novel Compound, 84F2, Inhibits Calmodulin Deficient RyR2" (2017). Dissertations and
Theses. Paper 3484.
https://doi.org/10.15760/etd.5368

This Dissertation is brought to you for free and open access. It has been accepted for inclusion in Dissertations
and Theses by an authorized administrator of PDXScholar. Please contact us if we can make this document more
accessible: pdxscholar@pdx.edu.

Novel Compound, 84F2, Inhibits Calmodulin Deficient RyR2

by
Robert Carl Klipp

A dissertation submitted in partial fulfillment of the
requirements for the degree of

Doctor of Philosophy
in
Applied Physics

Dissertation Committee:
Jonathan Abramson, Chair
Steve Reichow
Robert Strongin
Drake Mitchell

Portland State University
2017

© 2016 Robert Carl Klipp

Abstract
The cardiac ryanodine receptor (RyR2) plays a key role in excitation-contraction coupling
(ECC). Mutations in RyR2 are known to be linked to the arrhythmogenic disorder,
catecholaminergic polymorphic ventricular tachycardia (CPVT), a deadly disease which is
characterized by a leak of calcium from sarcoplasmic reticulum and a decrease in
calmodulin (CaM) binding. A novel drug, 84F2, shown to inhibit arrhythmias in RyR2R176Q heterozygous CPVT mouse hearts (2.5 µg/kg), decrease spark frequency in cells
derived from CPVT mice (IC50 = 35 nM), and inhibit RyR2 single channel activity at low
nanomolar concentrations (IC50 = 8 nM). When CaM is added back to RyR2, 84F2’s
ability to inhibit channel activity is suppressed approximately 250 fold. A metabolite of
84F2, 78F3, is shown to also be active in the inhibition of RyR2. We propose that 84F2
decreases arrhythmias by binding to the CaM deficient RyR2, but does not affect normal
ECC when CaM is present. This work characterizes for the first time a class of drugs
whose inhibitory affects are dependent upon the removal of CaM from RyR2.
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1

Introduction and Review of Related Literature

The contraction of muscle is responsible for nearly every facet of day-to-day life. The
heart, like any other muscle, relies upon the basic principle of muscle contraction. When
this fundamental process is disturbed, life can be drastically altered, or taken away.
Here we discuss the fundamentals of healthy cardiac muscle contraction, reviewing the
structure of contractile elements and how excitation-contraction coupling regulates
these structures. We highlight the importance of Ca2+ in the process of excitationcontraction coupling and how mishandling of Ca2+ leads to improper cardiac function,
resulting in arrhythmia, heart failure, and death. One source of Ca2+ mishandling,
dysfunction in the cardiac ryanodine receptor (RyR2), will be examined in its relation to
a genetic arrhythmogenic disorder, CPVT.
1.1

Excitation – Contraction Coupling

The process by which electrical signals generated in the nervous system propagate and
lead to contraction of muscle is referred to as excitation–contraction coupling (ECC).
Both the skeletal and cardiac muscle system undergo ECC, but their mechanism of
gating are different. Details of ECC in skeletal muscle will not be discussed in this work,
except to highlight key differences.
1.1.1 Cardiac Muscle Structure
The heart is separated into 2 major regions. The region where blood enters the heart,
the left and right atrium, and the region where blood is pumped to the rest of the body,
1

the left and right ventricles. Both of these regions are composed of muscle fibers made
up of cardiac muscle cells, or cardiomyocytes.
Contractile cardiomyocytes in the ventricle are composed of groupings myofibrils. These
myofibrils are formed from long chain of sarcomeres. This sarcomere is the contractile
element of the muscle fiber.
Thin filaments, composed primarily of actin, overlap with thick filaments, composed
primarily of myosin, to make up each sarcomere. These areas of overlap, known as Abands, give muscle its characteristic striated pattern. The area containing the thin
filament-actin, known as the I-band, is anchored at an area known as the Z-disk. Each
sarcomere spans between two Z-disks.
Surrounding each cardiomyocyte is a cellular membrane known as the sarcolemma. At
the Z-disks, the sarcolemma invaginates into the cardiomyocyte. These invaginations are
known as transverse, or T-tubules.
In a similar manner, myofibrils are surrounded by a web-like membrane system, known
as the sarcoplasmic reticulum (SR). Terminal cisternae (TC), which are enlarged regions
of SR, meet up with the T-tubules to form a junction. A key difference between cardiac
and skeletal muscle is that cardiac muscle forms a dyadic junction with one T-tubule and
one TC, while skeletal muscle forms a triadic junction, with two TC per T-tubule.

2

Figure 1.1 Schematic of a Cardiomyocyte
Schematic illustrating key structures involved with ECC within a cardiac muscle cell1.
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1.1.2 The Action Potential
The resting membrane potential of most cells ranges from -60 mV to -95 mV, with
reference to the extracellular space. For cardiomyocytes, the membrane potential is
typically -85 mV to -95 mV. This membrane potential primarily depends on a gradient of
sodium (Na+) and potassium (K+) ions driven by a Na+/K+-ATPase in sarcolemma, as well
as the membrane’s permeability to K+ in the cell’s resting state.
ECC begins in the right atrium’s sinoatrial (SA) node when pacemaker cells generate an
electrical signal. This signal propagates through the chambers of the heart via cardiac
muscle cardiac conduction system. This electrical signal triggers a change in membrane
potential in contractile cardiomyocytes throughout the heart. This change in membrane
potential is known as the action potential (AP).

Action potentials in cardiomyocytes are separated into five distinct phases:
Phase Zero - Depolarization: The electrical signal generated in the SA node activates voltagegated Na+ channels on the sarcolemma. This causes a rush of Na+ into the cytoplasm, rapidly
depolarizing the cell to membrane potentials of 20 mV to 30 mV.
Phase one - Partial Repolarization: The new membrane potential deactivates the voltagegated Na+ channels and activate voltage-gated K+ channels. The movement of K+ out of the
cell causes a small decrease in the membrane potential to values of 20 mV to -10 mV.
Phase Two - Plateau Phase: Ca2+ enters the cell through voltage gated L-type Ca2+ channels.
The K+ channels from phase one remain open. The net result is a balance of charge into and
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out of the cell resulting in a long plateau phase around 0 mV. The plateau phase is where
muscle contraction occurs.
Phase Three - Repolarization: Closure of L-type Ca2+ channels and the activation of the
Na+/Ca2+ exchanger (NCX), results in Ca2+ leaving the cell. Ca2+-dependent and voltagedependent K+ channels open, resulting in a repolarization of the cell.
Phase Four - Diastolic Phase: Also, known as the resting phase. In this phase, myocytes are at
their resting membrane potential. Once the resting potential is reached the voltagedependent K+ channels close.
1.1.3 Contraction of Muscle
Ca2+ in the cytoplasm, which becomes elevated during the AP, binds to and activates
troponin C, a protein linked to actin filaments. Troponin C, upon binding Ca2+, undergoes
a conformational change, allowing myosin heads to access the actin filaments. The
myosin head hydrolyzes adenosine triphosphate (ATP), shifting its position further down
the actin filament.
The shifting of the thin and thick filaments relative to each other has the net effect of
shortening the sarcomere. This process, carried out in each sarcomere, results in overall
shortening of muscle fibers and contraction of the muscle.
1.2

Calcium-Induced Calcium Release

Calcium plays a central role, in both the action potential, as well as in triggering the
contraction of muscle. In addition, the amount of Ca2+ in the cell is related to the
strength of contraction. Cytosolic Ca2+ is initially increased via L-type Ca2+ channels
during the AP, however, this increase in Ca2+ alone is not sufficient to trigger proper
5

muscle contraction. The SR within the cell serves as a secondary source of Ca2+,
releasing stores of Ca2+ during the AP and triggering muscle contraction.
1.2.1 Sarcoplasmic Reticulum
The sarcoplasmic reticulum, a modified endoplasmic reticulum, serves as a Ca2+ storage
system within myocytes. The SR forms two distinct regions, one which wraps along the
length of the myofibril (longitudinal SR), and the terminal cisternae, which forms the
dyadic junction with the T-tubules (junctional SR).
In cardiac muscle, Ca2+ entering the cell during the AP, via the L-type Ca2+ channels,
binds to and activates a Ca2+-release channel (CRC) found on the SR. This process is
referred to as Ca2+-induced Ca2+ release (CICR).
Junctional SR is near L-type Ca2+ channels found in the T-tubles. In addition, the CRC is
more abundant in the junctional SR than in the longitudinal SR. This structural
composition allows for near-simultaneous CICR, a critical component to proper ECC. In
cardiac muscle, dyadic junctions are the location of all ECC.
Following muscle contraction, Ca2+ levels are returned to diastolic levels. Most Ca2+
(~70%) is actively pumped back into the SR through its other major protein, the
sarco/endoplasmic reticulum Ca2+-ATPase (SERCA), found primarily (90%) in the
longitudinal SR. The remaining Ca2+ is extruded via the Na+/Ca2+ exchanger (NCX) and a
small portion through plasma membrane Ca2+-ATPases and mitochondrial uniporters.

6

CICR is another major distinction between cardiac and skeletal muscle. Skeletal muscle
interactions between the L-type Ca2+ channel and the CRC are not as well defined, but
are believed to have a physical coupling between them.

1.3

The SR Ca2+-Release Channel: The Ryanodine Receptor

At the center of CICR, ECC, and healthy cardiac function is the SR Ca2+-release channel,
the ryanodine receptor. Its name comes from its high affinity for the plant alkaloid,
ryanodine, while in its open conformation2. Ryanodine receptors are found highly
conserved throughout animal species and within the different muscle types.
Different isoforms of the ryanodine receptor are found in the three muscle types:
skeletal muscle (RyR1), cardiac muscle (RyR2), and smooth muscle (RyR3). These
isoforms of ryanodine receptor share an approximate 70% sequence homology between
them.
The three-dimensional structure was first determined for RyR1 using methods of cryoelectron microscopy in 19953. The cytoplasmic assembly of the receptor consists of four
identical monomers, together forming a homotetramer (290 Å X 290 Å x 130 Å). There is
also a smaller transmembrane assembly (120 Å X 120 Å x 70 Å) linking the SR lumen to
the myocyte cytoplasm. Altogether, the ryanodine receptor forms the largest known ion
channel with a total molecular weight of 2.3 MDa.

7

1.3.1 The Ca2+ Spark
The process of ECC starts with an electrical signal and results in the release of Ca2+ from
RyR2 by means of CICR. Many RyR2s are grouped in formations known as couplons at
the dyadic junction region. The opening of RyR2 results in a brief flux of Ca2+ out of the
SR into the cardiomyocyte. This Ca2+ release triggers other RyR2s in the couplon to
open. This release of Ca2+ from all RyR2’s within a couplon is termed as a Ca2+ spark4.
Ca2+ sparks can occur spontaneously, where a random RyR2 opening triggers a local Ca2+
spark event. Or, in the case of ECC the entry of Ca2+ into the dyadic junction triggers
many couplons resulting in simultaneous Ca2+ sparks in the myocyte. The total Ca2+ flux,
from all Ca2+ sparks, referred to as the Ca2+ transient, is responsible for muscle
contraction5.

1.3.2 Modulation of RyR2
Release of Ca2+ from the SR during ECC is a highly complex process subject to
modulation from cellular processes, associated proteins, cellular conditions, and nonphysiological elements.
In its native state, RyR2 exists as a complex of many associated proteins which together
regulate its function:
Calmodulin: Ubiquitous Ca2+-binding protein that binds to and modifies the state of RyR.
Discussed further in section 1.6.
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FKBP12: 12 kDa FK506 binding protein FKBP12 is mainly associated with RyR1, stabilizing the
closed conformation of the channel6.
FKBP12.6: 12.6 kDa FK506 binding protein. FKBP12.6 mainly functions as a regulator of RyR2,
stabilizing the closed conformation7. FKBP12 is found at much higher concentrations in RyR2
than FKBP12.6, but RyR2’s affinity for FKBBP12.6 is approximately 500 times that of FKBP12’s,
making FKBP12.6 the main regulator of the channel8.
Calsequestrin: 45 kDa low-affinity Ca2+-binding protein found in the SR lumen. Calsequestrin’s
main function is to increase the SR’s Ca2+ storage capacity. Each calsequestrin molecule binds
up to fifty Ca2+ ions9.
Triadin and Junctin: 35 kDa protein, triadin and 26 kDa protein, junctin are found in the
junctional SR. Both serve as anchors, coupling to calsequestrin and RyR2. Binding affinity for
calsequestrin to RyR2 is increased in the presence of low Ca2+.10
Dihydropyridine Receptor (DHPR): The DHPR (more commonly known by voltage-gated Ltype Ca2+ channel) is a 100 kDa protein involved in the AP as well as in triggering CICR. The
association between DHPR and RyR2 is not direct, as is believed to be the case in RyR1.

Cellular processes lead to phosphorylation of RyR2 by certain proteins. This
phosphorylation is known to modulate channel activity. Proteins known to play a role in
phosphorylation of RyR2 include:
Protein Kinase A (PKA): a 96 kDa protein which anchors to RyR2 through the muscle A kinase
anchoring protein (mAKAP). Elevated cAMP levels in the cell activate PKA. Once activated, PKA
phosphorylates RyR2 leading to increased activity11. Hyperphosphorylation of RyR2 by PKA is
strongly correlated with RyR2-dysfunction. The exact mechanism by which phosphorylation
leads to dysfunction is still debated in the literature (discussed in further detail in section 1.5).
Ca2+/Calmodulin-Dependent Protein Kinase 2 (CaMKII): CaMKII is a protein kinase which
becomes activated upon binding calmodulin in its Ca2+-bound form. Upon activation, CaMKII
9

can phosphorylate RyR2. CaMKII phosphorylation of RyR2 has been shown to both increase12
and decrease13 channel activity.
Protein Phosphatase 1 and 2a (PP1 and PP2a): PP1 and PP2a regulate channel activity by
dephosphorylating the channel, maintaining proper cellular homeostasis14.

In addition to proteins that associate with RyR2, there are many other physiological and
non-physiological modulators of RyR2. Some of the more important modulators include:
Ryanodine: High affinity plant alkaloid that is believed to bind in the pore of ryanodine
receptors15. Open receptors bind ryanodine with a higher affinity and can lock the channel in
an open state16.
Caffeine: Activates ryanodine receptor by making the channel mores sensitive to activation by
Ca2+.17
Ruthenium Red: Inhibitor of the channel
Calcium: Ca2+ is the key regulating ion of RyR2, governing its role in ECC. RyR2 has Ca2+ binding
sites on both the cytoplasmic and luminal faces. When Ca2+ levels in the cytosol are low
(approximately 1µM), a high affinity Ca2+ binding site on RyR2 activates the channel. At higher
Ca2+ concentrations (> 100 µM) Ca2+ binds to a lower affinity site which will inhibit the
channel18.
Magnesium: Mg2+ inhibits RyR2 by competing with Ca2+ for high affinity binding sites19. It is
believed to work by direct inhibition when binding to the low-affinity Ca2+ site. At the highaffinity site it is thought to compete with Ca2+, which prevents activation by Ca2+, resulting in a
more closed state20,21.
Tetracaine: A local anesthetic which can directly inhibit RyR2 activity22.
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1.3.3 RyR2-Dysfunction
Proper ECC is dependent on intricate cardiac structures, various protein interactions,
and critical timing of cellular processes. Disrupting any of these things can cause issues
in ECC, leading to serious complications including, arrhythmia, heart failure, and death.
There are a vast number of disorders that lead to electrical instability of the heart. The
exact mechanisms that result from these disorders in many cases is poorly understood.
One underlying factor common to these disorders is the mishandling of Ca2+ within the
cell.
Dysfunction of RyR2 can lead to a leak of Ca2+ during diastole. This Ca2+ leak can trigger
the Na+/Ca2+ exchanger, resulting in delayed afterdepolarizations (DADs) which may
lead to arrhythmia23. In addition, RyR2-Ca2+ leak can lead to increased expression of the
Na+/Ca2+ exchanger seen in failing hearts24, reduced SERCA activity25 and decreased SRCa2+ stores. Decreases in SR Ca2+ reduces the Ca2+ transient, resulting in weaker
contractile force associated with heart failure. These changes create a positive feedback
system which if left untreated can degenerate into arrhythmia and heart failure.
There are several diseases characterized by improper Ca2+-cycling due to RyR2 Ca2+-leak.
This work focuses on RyR2-dysfunction associated with catecholaminergic polymorphic
ventricular tachycardia (CPVT).
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1.4

Catecholaminergic Polymorphic Ventricular Tachycardia (CPVT)

CPVT made its first appearance in the literature in 1978. It is a genetic, arrhythmogenic
disorder affecting one in every ten thousand people. Most individuals with the disease
will experience first onset of symptoms within the first two decades of life. The first
symptoms often include dizziness and syncope, but can also lead to ventricular
fibrillation and sudden cardiac death. Without treatment, CPVT has a 30%-50% mortality
rate by the third decade of life26.
Electrocardiograms do not typically show signs of CPVT. Stress testing is necessary to
see the characteristic bidirectional ventricular tachycardia associated with the disease.
The best method of diagnosing CPVT is genetic testing for those individuals whose
family have a history of the disease. With no prior knowledge of the disease and the
dangers associated with first onset, CPVT is one the leading causes of sudden cardiac
death, especially among children.
The different forms of the disease deal with mutations in four different proteins, all of
which are associated with RyR2:
CASQ2 is an autosomal recessive form of the disease involving mutations in calsequestrin
CASQ2 accounts for 2% to 5% of incidences of CPVT27.
TRDN is an autosomal recessive for of the disease involving mutations in triadin.
CALM1 is an autosomal dominant form of the disease involving mutations in calmodulin
CALM1 accounts for less than 1% of all CPVT 28.
CPVT1 is an autosomal dominant form of the disease involving mutations in RyR2. CPVT1 is
the main form of the disease and conservative estimates show that it accounts for 50% to
12

55% of all CPVT29. CPVT1 is the main area of interest for this work, all further instances of
CPVT refer specifically to CPVT1.

1.4.1 CPVT1
There are many known mutations in RyR2 that lead to CPVT, resulting in improper
function. However, most cases of CPVT occur as a single point mutation occurring in one
of four main regions30:
Domain I (RyR2 amino acid sequence 77-466). Mutations in Domain I account for
approximately 18% of occurrences of CPVT.
Domain II (RyR2 amino acid sequence 2246-2534). Mutations in Domain II account for
approximately 19% of occurrences of CPVT.
Domain III (RyR2 amino acid sequence 3778-4959). Mutations in Domain III account for
approximately 22% of occurrences of CPVT.
Domain IV (RyR2 amino acid sequence 4497-49590). Domain IV accounts for approximately
22% of occurrences of CPVT.

These four domains are highly conserved across species as well as the differing isoforms
of the ryanodine receptor. It is known that mutations in these four domains in RyR1
correspond to central core disease (CCD) and malignant hyperthermia (MH). It has been
shown that specific point mutations known to cause CPVT in RyR2 will cause MH when
present in RyR131. This seems to indicate some mechanistic similarities RyR2/RyR1dysfunction and resulting diseases.
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1.4.2 CPVT Pathway Leading to RyR2-Dysfunction
When individuals with CPVT experience ventricular tachycardia (VT) it is usually under
times of stress and/or heavy exercise. During these periods the body elevates
catecholamine levels which trigger a cascade of events which lead to VT.
Epinephrine is raised in the body as a “fight-or-flight” response when under stress.
When this occurs, it binds to and activates the beta1-adrenergic receptor on the
sarcolemma. Upon activation, G-proteins, coupled to the receptor on the inner
membrane, activate adenylyl cyclase. Adenylyl cyclase, once activated, hydrolyzes ATP
into 3’,5’-cyclic adenosine monophosphate (cAMP). Elevated cAMP levels in the cell
activate protein kinase A (PKA), which then phosphorylates RyR2.
It is believed that this phosphorylation of RyR2 leads to a more open state of the
channel and in individuals with CPVT this leads to RyR2 dysfunction32.
1.4.3 Treatment for CPVT
CPVT has no known cure, treatment is typically targeted to preventing the onset of
occurrences with medication. Beta blockers are the most common class of drugs used to
treat CPVT. Beta blockers work by binding the beta1-adrenergic receptor and preventing
epinephrine from activating the receptor. Beta blockers have been shown to decrease
occurrence of CPVT symptoms in the short term, but long term use does not affect the
mortality rate from the disease33.
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Implantation of cardioverter defibrillators (ICD) are used for individuals whose
medication is not effective and/or have recurrent syncope. ICD are invasive and do not
prevent arrhythmia and run the risk of firing in the absence of arrhythmia.
Another medication, flecainide, can be prescribed for those whom beta blockers are not
effective. Flecainide works as a sodium channel and a RyR2 blocker and has been shown
to inhibit arrhythmias from CPVT in both mouse34 and clinical trials35, but can also lead
to worsened heart rhythm.
The lack of understanding regarding RyR2-dysfunction resulting from CPVT, the high
mortality rate associated with CPVT, and the drawbacks of current treatment options,
make the understanding and development of new treatments an important pursuit.
Furthermore, understanding of mechanisms involved in CPVT may enhance our
understanding of other RyR2-dysfunction related diseases.
1.5

Hypotheses of RyR2 Dysfunction

The mechanism responsible for RyR2 Ca2+ leak is still not fully understood and is
debated in the literature. Here we briefly discuss prevalent theories regarding RyR2dysfunction and their potential role in CPVT.
1.5.1 FKBP12.6 Dissociation
One theory of RyR2-dysfunction is the destabilization of the channel by the removal of
FKBP12.6. FKBP12.6 has been shown to stabilize RyR236, and its removal leads to a more
open channel.
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Heart failure is often associated with hyperphosphorylated RyR2. Dissociation of
FKBP12.6 has been linked to PKA phosphorylation of RyR2 and its removal has been
shown to Increase RyR2 Ca2+-sensitivity31. This increase in Ca2+-sensitivity may be the
underlying cause of RyR2 Ca2+ leak. Furthermore, reduced FKBP12.6 affinity has been
seen in RyR2 with known CPVT mutation, R247S37,38.
Although initial evidence seemed to support the theory of FKBP12.6 dissociation leading
to RyR2 malfunction in diseased states such as CPVT, it has become more controversial
in recent years. Studies have shown differing results involving FKBP12.6 removal via PKA
phosphorylation. One study showed that phosphorylation of RyR2 did not cause
FKBP12.6 to dissociate39. The R247S mutation has been shown to increase FKBP12.6
affinity40 and other studies involving CPVT mutations have shown no reduced affinity for
FKBP12.641,42.

1.5.2 Oxidation
Glutathione/glutathione disulfide (GSH/GSSG) ratios within the cell maintain the redox
potential. Redox potential is a measure of how easily something can become oxidized or
reduced. Ca2+ handling within cardiomyocytes is known to be influenced by the redox
potential of the cell. There are known to be between 300-400 cysteine residues with
thiol side chains on RyR2 which are sensitive to oxidation43.
It has been hypothesized that these thiol residues play a critical role in the state of RyR2.
A strong correlation has been shown between inhibition of the receptor in the presence
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of strong electron donors and activation of the channel when treated with electron
acceptors44.
Reactive oxygen and nitrogen species such as H2O2 and NO influence the GSH/GSSG
ratio. These species become elevated due to factors such as exercise, diet, and
environmental factors. If the ROS and RNS become too high cells undergo oxidative
stress, which can lead to a destabilized channel.
1.5.3 Domain Unzipping
Domain unzipping, first proposed by Ikemoto and Yamamoto45, refers to an interaction
between the N-terminal and central domain of RyR2. These domains remain “zipped”
when RyR2 is in a stabilized state. In a malfunctioning receptor, it is believed that these
domains become “unzipped” and the channel becomes more sensitive to activators
such as Ca2+. It has been shown that a single point mutation in either of these domains
can lead to a heightened sensitivity to channel activators. Failing hearts with reduced SR
Ca2+ content, and diastolic Ca2+ leak have been accompanied with a weakened domain
interaction46.
1.5.4 Calmodulin Dissociation
Recently, the literature has suggested that dissociation of CaM from RyR2 may be a
critical component in increased RyR2 Ca2+ leak47. As the primary focus of this work, CaM
and its relation to RyR2-dysfunction in CPVT will be discussed in detail.
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1.6

Calmodulin

Calmodulin (CaM) is a highly conserved and ubiquitous Ca2+-binding protein. CaM is
involved in regulating numerous cellular processes. Its structure was first determined by
X-ray crystallography in 198548 as well as NMR in 199549. CaM has 148 residues and a
total molecular weight of 16.7 kDa.
Its structure consists of two globular EF hands which bind Ca2+ ions, two at each globular
head. The two globular heads are connected by a flexible helix tether. When Ca2+ binds
to CaM, it undergoes a conformational change, exposing hydrophobic residues. In its
Ca2+-bound state, CaM interacts with over thirty target proteins including: Adenylyl
Cyclase, Myosin Light Chain Kinase, Phosphodiesterase, L-Type Ca2+ Channels, and the
Ryanodine Receptor.
In cardiomyocytes, CaM concentrations have been reported to be between 2-5 µM50.
Approximately 95% of CaM is bound to its target proteins in the cell, 20% is believed to
be bound to RyR251. Free CaM in cardiomyocytes ranges between 50-75 nM52.
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Figure 1.2 Structure of Calmodulin
3-Dimensional structure of CaM in its Ca2+-free form. Structure from PDB source53.
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1.6.1 Calmodulin Interaction with the Ryanodine Receptor
CaM is known to be a modulator of both skeletal54 and cardiac ryanodine receptors55. It
is also believed to interact with RyR356 but has been poorly characterized. CaM’s effect
on both RyR1 and RyR2 will be discussed here to contrast potential correlations
between diseases, as well as to highlight discrepancies in studies involving CaM and
RyR2.
1.6.1.1 Calmodulin Binding to the Ryanodine Receptor
RyR1 binds CaM in both its Ca2+-free (ApoCaM) and Ca2+-bound (CaCaM) forms57.
Furthermore, RyR1 has been shown to bind both forms at a single, high affinity, binding
site corresponding to RyR1 residues 3614-364358. CaM, in either form, binds to RyR1
with a stoichiometric ratio of four CaMs per RyR1 tetramer, or one CaM per monomer59.
Like RyR1, CaM has been shown to have one, high affinity, binding site on RyR2,
corresponding to residues 3583-3603 in both its ApoCaM and CaCaM form60. Most
reports have shown that four CaM bind per RyR2 tetramer in purified RyR2. One study
showed that in its native form, RyR2 bound 8 CaMs per tetramer61.
1.6.1.2 Calmodulin Modulation of the Ryanodine Receptor
ApoCaM is a known activator of RyR162 and CaCaM is an inhibitor of RyR163. As in the
case of RyR1, CaCaM is an inhibitor of RyR264. However, ApoCaM’s effect on RyR2 is still
poorly understood, with many conflicting results reported in the literature.
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Ca2+ release from cardiac SR vesicles showed no change in the presence 1 µM ApoCam,
identical experiments carried out on skeletal SR showed that ApoCaM increased rate of
Ca2+ release, indicating activation65. This study went on to show that Ca2+-dependent
activation of RyR1 was shifted to lower Ca2+ levels (kd = 360 nM to kd = 60 nM), again,
no change in Ca2+ activation was seen in RyR2 under identical conditions.
In a different study looking at RyR2 single channel activity, it was seen that in the
presence of 2 µM cytosolic Ca2+, CaM reduced the open probability of the channel by
25-fold, indicating that CaCaM acts as strong inhibitor of RyR2. When the same
experiment was performed with a mutant CaM, CaMD1234, incapable of binding Ca2+, no
change in RyR2 open probability was seen66.
Balshaw, et al. showed that unlike previous reports, CaM inhibited ryanodine binding at
low (<1 µM) Ca2+ levels, making the channel less sensitive to Ca2+ activation67. Table 1.1
summarizes CaM’s effect and interaction with RyR1 and RyR2.

Table 1.1 Summary of Calmodulin's Effect on RyR1 and RyR2
ApoCaM Modulation
CaCaM Modulation
ApoCaM Stoichiometry
CaCaM Stoichiometry

RyR1
Activator
Inhibitor
4 per Tetramer
4 per Tetramer
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RyR2
Differing Results
Inhibitor
4 per Tetramer
4 or 8 per Tetramer

1.6.2 Calmodulin and RyR2-Dysfunction
Calmodulin is known to be involved in the regulation of RyR2 conformation. Growing
evidence in the literature suggests that cardiac diseases caused by RyR2-dysfunction,
like CPVT, may be due to CaM dissociation from RyR2, resulting in improper Ca2+ cycling
during ECC.
Early hypotheses in the literature suggested that CaM may play a role in maintaining
normal ECC, terminating the release of Ca2+ from SR by inhibiting RyR2 while in its
CaCaM form68. Evidence in the literature has since supported this hypothesis.
Studies have shown that RyR2’s affinity for CaM is reduced when mutations are made in
RyR2’s CaM-binding region. These mutations result in sustained Ca2+ transients, reduced
CaCaM inhibition at the single channel level, and reduced CaCaM inhibition in 3Hryanodine binding69. Cardiomyocytes from failing hearts with an increased occurrence of
Ca2+ sparks, indicative of RyR2-dysfunction, show that addition of CaM restores the
occurrence of Ca2+ sparks to levels seen in healthy cardiomyocytes70.
These studies show that improper cardiac function is often accompanied with CaM
dissociation from RyR2, and restoring CaM association to RyR2 can restore proper
function. This evidence supports the hypothesis that CaM dissociation may be a critical
component in RyR2-dysfunction leading to improper Ca2+ cycling in cardiac diseases.
One study used a knock-in (KI) CPVT mouse model (R247S in RyR2) to show that,
following PKA phosphorylation, RyR2 had reduced CaM binding affinity. Following
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phosphorylation, the occurrence of Ca2+ sparks increased in the KI mice. In WT mice,
phosphorylation of RyR2 had no effect on CaM binding affinity or the occurrence of Ca2+
sparks71. Phosphorylation of RyR2 was shown to be equal in both the WT and KI.
Interestingly, in the absence of PKA phosphorylation, RyR2 affinity for CaM was equal in
both the WT and KI mice. Further studies have shown that binding affinity of CaM to
RyR2 is decreased, even in the absence of PKA phosphorylation72,73.
These studies show that RyR2’s CaM binding affinity is reduced in CPVT. Following PKA
phosphorylation this reduction in affinity is accompanied by arrhythmogenic properties
of cells. Normal cells that show no reduction in CaM binding affinity to RyR2 do not
result in arrhythmogenic states following PKA phosphorylation.
Faulty interaction between RyR2 and CaM is believed to play an important role domain
unzipping, a hypothesis for RyR2-dysfunction and CPVT. The RyR2 sequences believed to
be involved domain unzipping overlap strongly with CPVT mutations. The main domain
peptide used in domain unzipping studies, DPC10 (RyR2 residues 2460-2495), is known
to activate RyR2 leading to an arrythmogenic state. In the presence of DPC10, WT
cardiomyocytes have been shown to have reduced CaM binding and increase CaSPF74.
When the cardiomyocytes were first pre-incubated with CaM and then treated with
DPC10, binding of DPC10 was reduced and CASPF did not increase. FRET showed that
CaM and DPC10 indicating that the inhibitory effect one has on the other is allosteric.
Although, domain unzipping is not the focus of this work, these studies further illustrate
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that CaM plays a role in proper function of RyR2 and that CPVT like states of the channel
show faulty CaM interaction.
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2
2.1

Methods and Materials
Preparation of SR Vesicles

Isolation of sheep cardiac SR vesicles follows a modified protocol from Williams75. Sheep
hearts collected immediately following anesthetization of sheep are rinsed of excess
blood and transported on ice from Oregon Health and Sciences University to Portland
State University in a homogenization buffer: 300 mM sucrose, 10 mM PIPES, 0.5 mM
PMSF, 1 µg/mL Leupeptin, pH 7.4 with KOH.
Upon arrival to Portland State the atria along with fatty tissue are removed and
discarded. The ventricles are cut into 1 cm3 pieces and divided equally into two 500 mL
beakers of homogenization buffer. Each batch is homogenized in a warring blender for
20 seconds at top speed, followed by a second 30 second wait period and blended for a
final 20 seconds at top speed.
Following homogenization, both batches are divided equally into 6 Type-19 rotor tubes
and spun at 9000 X G in a Beckman type-19 rotor for 20 minutes to remove cell debris.
Supernatant is filtered through four layers of cheese cloth and split into 6 type-19 rotor
tubes followed by centrifugation at 44,000 X G for 75 minutes.
The pellet is retrieved and resuspended in a buffer containing: 300 mM Sucrose, 400
mM KCl, 0.5 mM EGTA, 0.5 mM CaCl2, 0.5 mM MgCl2, 0.5 mM PMSF, 1 µg/mL Leupeptin,
25 mM PIPES, pH 7.0 with KOH. Pellet along with buffer are put into a single type-60
centrifuge tube and spun at 50,000 RPM in a type-60 Beckman Rotor for 30 minutes.
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The pellet is resuspended in buffer and homogenized with a glass homgenizer and
stored as 300 µL aliquots in liquid Nitrogen.
2.2

Protein Concentration Determination

Cardiac SR protein concentration is measured using the method of Kalckar76. Using an
Agilent 8435 UV-Visible spectrophotometer absorbance of set volumes of SR is
measured at 230 nm, 260nM, and 280nM. These absorbance peaks correspond to the
protein backbone, nucleic acid correction, and tyrosine/tryptophan maximum
absorbance. Protein concentration is then determined using the following equations:

Equation 2.1

 mg 
SR  = 1.45( Abs280 ) − 0.74( Abs260 )
 mL

Equation 2.2

 mg 
SR  = 0.185( Abs230 ) − 0.075( Abs260 )
 mL 

2.3

Purification of RyR2

RyR2 was purified and reconstituted into proteoliposomes following a modified protocol
of Meissner77, for the purification of RyR1. Crude cardiac SR is first separated into
junctional (heavy) and longitudinal (light) SR by centrifugation in a SW-28 rotor at
103,000 X G for 2 hours on a discontinuous sucrose gradient (0.3 M, 0.8 M, 1.0 M, 1.2
M, 1.5 M, 230 µM PMSF, 1 µM Leupeptin, 10 mM Imidazole, pH 7.4 with KOH).
Heavy SR is collected at the 1.2 M/1.5 M interface and resuspended 1:1 in resuspension
buffer (0.3 M sucrose, 10 mM imidazole, pH 7.4). Buffer and heavy SR is centrifuged for
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40 minutes at 95,000 X G in a Ti-60 rotor. Supernatant is discarded and pellet is
resuspended into the resuspension buffer (less than 5 mL total). Protein concentration is
determined as described in section 2.2. Heavy SR is separated into 200 µL aliquots and
stored in liquid nitrogen until use.
12 mg of heavy SR is solubilized to a concentration of 1 mg/mL in solubilization buffer
(CHAPS, PC, NaCl, PIPES, EGTA, Pefabloc, DTT) for 1 hour on ice by stirring. Following
solubilzation, 2 mg is placed onto a discontinuous sucrose gradient (7%-15% sucrose,
NaCl, PIPES, CHAPS, PC, Pefabloc, Leupeptin, DTT, CaCl2, EGTA, cAMP, pH 7.4, prepared
in cold room). 6 tubes in total are placed into an SW-28 rotor and centrifuged at
89,454XG for 17 hours.
1 of the 6 tubes contains heavy SR incubated with 3H-ryanodine. Following
centrifugation, 2 mL fractions are taken from the gradient containing 3H-ryanodine,
filtered and activity is measured. The fraction containing the highest counts is kept from
the other 5 gradients and pooled. The samples are dialyzed at 100X volume over 44
hours with 3 buffer changes (NaCl, PIPES, EGTA, CaCl2, PMSF, DTT) in the cold room.
Dialyzed samples are collected and centrifuged in buffer (PIPES, EGTA, CaCl2, PMSF) in a
Ti-60 rotor at 163,520XG for 2 hours. Pellet containing purified RyR2 is collected and
homogenized in buffer (NaCl, PIPES, Sucrose), aliquoted into 50 µL samples and stored
in liquid nitrogen until use in experiments.
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2.4

Single Channel Recordings

2.4.1 Planar Lipid Bilayers
Planar lipid bilayers were formed using the method originally published by Mueller et.
al78. Two chambers representing the myocyte cytoplasm (CIS) and SR lumen (TRANS) are
separated by a small aperture. A pipette tip dipped in a lipid mixture is used to create a
monolayer over this aperture. After the chambers are filled with solution, a second
pipette tip is used to apply a second monolayer over the aperture.
The two monolayers hydrophobic tails will face the hydrophobic solvent separating
them, the hydrophilic head groups face the aqueous solution in the chambers. The Van
der Walls force between these two monolayers force these two monolayers together
pushing out the solvent and forming a bilayer. This spontaneous process of thinning
results in bilayers of varying resistances. Capacitance and current leak of the bilayer is
monitored. Bilayers may be thinned further by manually dragging a small bubble over
the aperture where the bilayer is formed until the desired capacitance is reached. A
desired capacitance for a 150 µM aperture is between 40 pF to 100 pF and shows a
good square wave pattern.

2.4.2 Solutions and Material
Bilayer chambers were made from acetyl or delrin in the Portland State University
student machine shop. The construction consists of a base which has two openings, one
which holds the CIS solutions and one which holds a cylindrical cup which holds the
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TRANS solution. The cup interface between the two chambers is thinned to
approximately 150 µM and a small hole (100 µM – 200 µM) is drilled through this
interface. It is believed that an aperture roughly the same diameter as the thickness
promotes fusion into a bilayer.
The lipid mixture used to create the bilayer is composed of a 5:3:2 mixture of
DOPE:DOPS:DOPC (DOPE: 1,2-Dioleoyl-sn-Glycero-3-Phosphoethanolamine; DOPS: 1,2Dioleoyl-sn-Glycero-3[phosphor-L-serine]; DOPC: 1,2-Dioleoyl-sn-Glycero-3phosphocholine) suspended in a hydrophobic solvent (n-decane) at a concentration of
33 mg/ml. Lipids are purchased from Avanti Polar Lipids (Alabaster, USA).
All bilayer work is done with the CIS chamber is filled with 250 mM KCl, 15 mM HEPES,
and 100 µM CaCl2 at pH 7.4. The TRANS chamber is filled with 25 mM KCl, and 15 mM
HEPES, at pH 7.4. Following vesicle fusion the TRANS chamber is brought to 250 mM KCl
with a 2.5 M KCl, 15 mM HEPES, pH 7.4 solution. The CIS chamber’s free Ca2+ is chelated
to 25 µM with EGTA, as determined by the program Bound and Determined. In certain
experiments a salt concentration of 400mM KCl was used following the same methods
as above.
2.4.3 SR Fusion
Once a desired bilayer is formed, crude cardiac SR vesicles or purified RyR2
reconstituted into proteoliposomes from sheep heart are added to the CIS chamber,
over time these will incorporate into the bilayer resulting in a “fusion event.” The initial
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salt gradient is set up to swell the bilayer; this creates a larger surface area promoting
protein fusion. It is also believed that the vesicles aggregate at the bilayer surface, the
ionic difference on either side of the bilayer will cause H2O to pass into the vesicles from
the TRANS chamber causing the vesicles to swell and rupture. When the vesicles
rupture, they integrate into the bilayer resulting in protein fusion.
After fusion, the chambers are brought to equal ionic concentrations, this prevents
further fusions from occurring. It is desirable to have only one channel present at a time
due to the increasing instability of the bilayer with more fusions, as well as for analysis
purposes. Some data was recorded in the presence of two and in rare cases three active
channels.
2.4.4 Recordings
After fusion occurs and chambers are equalized, data is ready to be collected. Current is
measured via two Ag/AgCl electrodes submerged in electrically conducting salt bridges
(Agarose, 4M CsCl). The electrodes connect to a pre-amplifier which then connects to a
Warner BC535 amplifier. The signal is then digitized through a Digidata 1322A digitizer
and the measurements are recorded in ClampEx patch clamp chart recorder (pClamp
9.0). The preamplifier and chambers are housed within a faraday cage which is closed
off during data collection. The signal is digitally filtered at 1 kHz low pass filter and
sampled at (sampling rate) Recordings are made for no less than 2-3 minutes for each
condition, prior to each there is a 30 second period of stirring the solutions in both the
CIS and TRANS chambers.
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Recordings are made in the presence of a holding potential of +36 mV with the TRANS
chamber held at virtual ground. RyR2 is not a voltage gated channel but a voltage is
applied as a driving force due to the equal ionic concentrations between the two
chambers. Certain experiments were performed at different holding potentials to see if
there was a voltage dependent effect in the data.
RyR2 is a Ca2+ ion channel, however, K+ is used as the charge carrier in bilayer
experiments for two reasons. First, the conductance of RyR2 is larger for K+ than it is for
Ca2+.79 Secondly, Ca2+ modulates the activity of the channel.
Unlike SR vesicles, it is possible for the purified RyR2 reconstituted into proteoliposomes
to fuse with the cytoplasmic assembly facing the TRANS chamber. To ensure that all
data used is with the cytoplasmic assembly facing the CIS chamber, purified RyR2 is
tested for its orientation in the bilayer by monitoring its gating as a function of Ca2+. The
cytoplasmic assembly is more sensitive to Ca2+ and activity will decrease as a function of
decreasing Ca2+. Channels that were not sensitive to cytoplasmic Ca2+ were not used in
the final analysis of the given compound’s dose-response.
Artificial lipid membranes are often subject to current leak over time which can lead to
bilayer breakage. This leads some data sets to be absent of full dose-response
recordings.
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2.4.5 Analysis
2.4.5.1 Event Detection
Clampfit software (pClamp 9.0) is used to generate an events list of data using a halfamplitude threshold technique. A baseline level is manually set in the program along the
closed state of the recording. A second level is set representing the open state of the
channel; in cases where there is more than one channel, more levels can be set to
represent openings for multiple channels. Any event that is at least 50% the open state
conductance, is treated as an open event and the program measures the length (dwell
time) of the event.
2.4.5.2 Open Probability
The main method of determining a compound’s effectiveness in inhibiting RyR2 is
determining the open probability (Po) over a range of concentrations. Po represents the
probability of a channel being in an open state. A Po of 1 represents a channel is open
100% of the time and a Po of 0 represents a channel that is completely closed. Clampfit
determines the Po as the fractional amount of time the channel is open:

Equation 2.3

Po =

To
To + Tc

Equation 2.4

To = to1 + to2 + to3 + ...+ ton

Equation 2.5

Tc = tc1 + tc2 + tc3 +...+ tcn

Dose-Response curves are generated from the open probabilities and fit to a fourparameter logistic equation.
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2.4.5.3 Open and Closed Dwell Times
In addition to measuring the open probabilities of channels, the open and closed dwell
times are examined. Po depends on the open dwell time (To), closed dwell time (Tc),
and frequency of fluctuation. The Po can be changed by modifying any of these
parameters and to better understand the kinetics of gating and how a compound is
changing the Po the average open and closed dwell times are examined.
Using the methods of Sigworth and Sine80 open and closed dwell times are compiled
into a histogram. Events vs. dwell times are binned logarithmically which centers at the
average dwell time.
2.4.5.4 Determination of Statistical Significance of Dwell Times
Statistical significance was determined for the dwell times. Dwell times at each
concentrations were compared to the control using a t-test.

t=

Equation 2.6

Equation 2.7

S X 1X 2 =

X1 − X 2
 1
1 

S X 1 X 2 
+

n
1
n
2



( n1 − 1) S X2 1 + ( n 2 − 1) S X2 2
n1 + n 2 − 2

Where n1, n1 are equal to the sample sizes. X1 and X2 are the averages. S1 and S2 are the
standard deviations. p-values were then calculated and a p-value less than 0.05 was
taken to be significant.
33

2.5

Ryanodine Binding

2.5.1 Equilibrium Binding
Ryanodine is a plant alkaloid that binds to the ryanodine receptor with high affinity
when the receptor is in an open conformation. Tritium labelled Ryanodine (3HRyandoine) can then be used to probe the “openness” of a population of SR vesicles
under varying conditions. Strong inhibitors of the ryanodine receptor should place the
receptor in a more closed conformation and therefore there should be less total
ryanodine binding.
Varying concentrations of 84F2 and metabolites were combined in test tubes containing
binding buffer (250 mM KCl, 15mM NaCl, 20 mM PIPES, pH 7.4 with KOH), crude cardiac
SR vesicles (0.25 mg/mL), 25 µM CaCl2, 13 nM unlabeled ryanodine, and 2 nM 3HRyanodine. Test tubes are added to a hot water bath (37 °C) for 3 hours which allows
ryanodine binding to reach equilibrium.
The incubation is quenched by rapid filtration through Whatman glass fiber filters using
a 24 or 48 cell Brandel Cell Harvester. Filters are washed of excess non-bound ryanodine
using a wash buffer (250 mM KCl, 20 mM TRIS, 15 mM NaCl, 100 µM CaCl2, pH 7.4 with
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KOH). Filters are added to 5 mL scintillation vials and 3 mL of CytoScint scintillation fluid
is added.
After the vials are shaken for 24 hours, a Beckman LS 6000 was used to measure the
activity present in each vial. Using the activity measured, the known total activity used
in each sample, and subtracting off for non-specific ryanodine binding (measured with
200 nM unlabeled ryanodine and 4 mM EGTA), concentration of ryanodine bound per
milligram of protein is calculated.
2.5.2 Rate of Binding
Ryanodine binding rates can be measured similar to equilibrium binding with the
following changes: Incubation is started with the addition of 3H-ryanodine into the test
tubes at 37 °C. Instead of a 3-hour incubation, samples are incubated for different time
lengths (typically 5, 10, 15 and 20 minutes) and quenched immediately. Samples are
measured as in equilibrium binding except no non-specific binding is subtracted. Each
condition is plotted as the amount of 3H-ryanodine bound vs. time. Points are fit to a
standard linear fit where “a” represents the rate of binding and y0 is equivalent to nonspecific binding:
Equation 2.8

y = ax+ y0

Rate of binding is examined as a function of concentration of compound to determine if
inhibition of binding rate occurs.
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3

Basis of Study

Ca2+ leak from SR is often the underlying cause in many cardiovascular disorders.
Dysfunction in RyR2, the source of Ca2+ leak, can lead to DADs, arrhythmia, reduced SRCa2+ load, cardiac restructuring, reduced contractility, heart failure, and death.
CPVT is one disorder where a mutation in RyR2 is characterized by improper Ca2+
handling. Treatment for CPVT, as well as other RyR2-associated cardiovascular diseases,
has primarily relied on medication targeted at preventing the onset of hyperadrenergic
states of cardiomyocytes.
RyR2-dysfunction, as the main source of improper Ca2+ cycling in many of these
disorders makes it a prime target for treatment. Preventing the leak of Ca2+ from RyR2,
with drugs specifically designed to inhibit the channel, could be a novel approach of
treatment for not only CPVT, but other RyR2/RyR1-associated diseases. In addition, by
understanding the mechanisms and effects of these drugs, our understanding of RyR2dysfunction can be enhanced.

3.1

Design of Therapeutic Drugs

Treatment of RyR2 Ca2+-leak relies upon drugs which strongly inhibit the channel. There
are many known inhibitors and activators of RyR2. Among these compounds a trend
was observed. Compounds that inhibited RyR2 tended to be electron donating, while
activators of RyR2 were electron acceptors. It was further shown that a correlation
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existed between the strength of the donor/acceptor and the potency of
inhibition/activation81.
Working with the hypothesis that strong electron donors tend to be potent inhibitors of
RyR2, many compounds were designed to target and inhibit RyR2. Using the structure of
tetracaine as a base, a known inhibitor of RyR2, derivatives designed to have stronger
electron donating properties, were systematically tested in a Ca2+-spark frequency
(CaSPF) screening assay. Those compounds which exhibited promising results were
further screened in a variety of assays for their potential to treat RyR2-dysfunction.
3.1.1 84F2 and Metabolites
The primary focus of this work is on the novel compound, 84F2. 84F2 was designed with
an ester linkage to allow easy passage across the sarcolemma. This ester linkage can be
hydrolyzed in vivo, which upon cleavage breaks into the compounds, 78F3, and 2(Diethylamino)ethanol (DEAE).
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Figure 3.1 Structures of 84F2, 78F3, and DEAE
Chemical structures of 84F2 and its two metabolites following the ester cleavage. A) 84F2. B) 78F3. C)
DEAE
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3.2

Initial Results

Experiments involving 84F2 were first carried out by our collaborators in the Wehren’s
Lab at Baylor School of Medicine. These laid the foundation for the work that follows.
3.2.1 Ca2+ Spark Assay
When the SR releases Ca2+, via RyR2, local spikes in Ca2+ trigger other nearby RyR2
molecules to open and release their Ca2+, resulting in a Ca2+ spark. Using a Ca2+-sensitive
fluorescent dye, this release of Ca2+ can be measured. The frequency of the Ca2+ sparks
gives insight into how the cell is functioning. An increase in the Ca2+ spark frequency
(CaSPF) is characteristic of an arrhythmogenic state of the cell.
To initiate the increase in Ca2+ spark frequency (CaSPF) cells are treated with
isoproterenol, mimicking a hyperadrenergic state associated with an arrhythmia.
Healthy cells have very few Ca2+ sparks, even under adrenergic stimulation. Cells with
RyR2-dysfunction, will show an increase in CaSPF following treatment with
isoproterenol.
Cardiomyocytes taken from mice with CPVT mutation, RyR2R176Q/+, which have been
shown to have increased CaSPF under adrenergic stimulation82, were used to test
compounds for their effectiveness in treating arrhythmias resulting from CPVT.
84F2 was tested in a dose-dependent manner using these RyR2R176Q/+ cells. Figure 3.2
shows the dose-response of 84F2 tested on CaSPF from RyR2176Q/+ cells. 84F2 shows a
strong potency in inhibition of the CaSPF, resulting in an IC50 = 35.40 nM.
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84F2 resulted in no decrease of Ca spark amplitude that was induced by field
stimulation (data not shown here). The amplitude reflects changes in the Ca2+ transients
related to ECC. This result with 84F2 indicates that normal ECC was not altered.
In addition to 84F2, its metabolite, 78F3, was tested in a manner identical to 84F2.
Figure 3.3 shows the dose-response of 78F3 on RyR2R176Q/+ cells in an arrhythmogenic
state. 78F3 shows an inhibition of the CaSPF with an IC50 = 200 nM.
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Figure 3.2 84F2 Inhibits CaSPF from RyR2R176Q/+ Cardiomyocytes
84F2 inhibits stimulated Ca2+ spark activity in RyR2R176Q/+ cardiomyocytes from mice. Cardiomyocytes with
increased CaSPF, induced by adrenergic stimulation, were potently inhibited by 84F2. IC50 = 35.40 nM.
This work was carried out in the Wehren’s Lab at Baylor School of Medicine.
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Figure 3.3 78F3 Inhibits CaSPF from RyR2R176Q/+ Cardiomyocytes
78F3 inhibits stimulated Ca2+ spark activity in RyR2R176Q/+ cardiomyocytes from mice. Cardiomyocytes with
increased CaSPF, induced by adrenergic stimulation, were potently inhibited by 78F3. IC50 = 200 nM. This
work was carried out in the Wehren’s Lab at Baylor School of Medicine.
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3.2.2 Monitoring Arrhythmia at Whole Animal Level
84F2 was also tested at the whole animal level. Simultaneous recordings of 6-lead ECG
as well as intercardiac electrograms are simultaneously recorded in adult (2-3month
old) mice with the RyR2R176Q/+ mutation. After induction of anesthesia (1.5% isoflurance
in 95% O2), baseline and intercardiac electrogram recordings are made. Next, inducibility
of ventricular tachycardia is determined using overdrive pacing and premature stimulus.
These measurements are carried out both with and without intraperitoneal (i.p.)
injection of 84F2.
Figure 3.4 shows 84F2’s effect at suppressing arrhythmia at the whole animal level.
Figure 3.4A shows that wild type (WT) mice exhibit normal sinus rhythm, while sinus
rhythm from RyR2R176Q/+ mice exhibit bidirectional and sustained ventricular tachycardia
(VT) following treatment with isoproterenol and electrical stimulus (indicated by
arrows). Following I.P. injection of 84F2, VT was clearly diminished in RyR2R176Q/+ mice.
Figure 3.4B summarizes the results, showing that the incidence of induced VT is greatly
reduced in RyR2R176Q/+ mice, following treatment with 2.5 µg/kg 84F2.
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Figure 3.4 84F2 Suppresses the Induction of Ventricular Tachycardia (VT) in
RyR2R176Q/+ mice
A) Representative simultaneous recordings of surface ECG and intracardiac electrograms after S1-S2
extrastimuli (indicated by arrows) revealed bidirectional and sustained VT in RyR2R176Q/+ mice treated with
placebo, or sinus rhythm in RyR2R176Q/+ mice treated with 02-84F2. B) Bar graph summarizing incidence of
reproducible VT induced by S1-S2 extrastimuli and significant decrease in VT treated with 02-84F2. This
work was carried out in the Wehren’s Lab at Baylor School of Medicine.
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3.3

Goal of Study

Initial experiments from our collaborators show that 84F2 potently inhibits
arrhythmogenic states arising from adrenergic stimulation of CPVT cells, as well as
significantly diminish the incidence of VT at the whole animal level. In addition, cells and
whole animals treated with 84F2 show normal ECC.
These results show important characteristics of what an ideal drug designed to treat
arrhythmia should have: alleviation of arrhythmia and no detrimental effects on cardiac
function following treatment. 84F2, having these properties, makes it a promising
candidate for therapeutic treatment for CPVT and other RyR2-mediated Ca2+ leak
diseases.
The results also present a fundamental question underlying RyR2-dysfunction. RyR2 leak
of Ca2+ can lead to cardiac disorders, however, the release of Ca2+ from RyR2 is essential
to ECC. By studying the mechanisms involved in 84F2’s inhibition of RyR2, our
understanding of what leads to RyR2-dysfunction may be enhanced.
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4

Results: Determination if 84F2 Directly Inhibits Purified RyR2

The decrease in CaSPF from RyR2R176Q/+ cardiomyocytes indicates that RyR2 is inhibited
in the presence of nanomolar concentrations of 84F2. However, it is not clear whether
this inhibition of RyR2 is due to an indirect or direct effect on RyR2 activity. 84F2 was
designed around the known RyR2 inhibitor, tetracaine, suggesting that the results seen
at the cellular and whole animal level are the result of the direct inhibition of RyR2 by
84F2.
Hypothesis 1: 84F2’s mechanism of treating arrhythmia is through the direct inhibition
of RyR2.
To test this hypothesis, purified RyR2 single channels were used in a planar lipid bilayer
to determine if 84F2 directly inhibits RyR2.
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4.1

84F2 Inhibition of Purified RyR2 at the Single Channel Level

RyR2, purified and reconstituted into proteoliposomes as described in the methods, was
incorporated into a planar bilayer and single channel activity was measured as a
function of 84F2 concentration.
Figure 4.1 shows representative single channel recordings of an experiment carried out
with 84F2. Trace A shows a control recording done in the presence of 25 µM cytosolic
Ca2+ and no 84F2. This recording yielded an average open probability (Po) of 0.97,
indicating that the channel spends 97% of the time in an open state. Subsequent
recordings B, C, and D show channels in the presence of 3 nM, 5 nM, and 35 nM 84F2.
These recordings yield channels Po measurements of 0.43, 0.28, and 0.05, respectively.
Subsequent recordings on this channel at higher 84F2 concentrations completely
inhibited all channel activity. 84F2 is seen here to inhibit purified RyR2 in a
concentration-dependent manner.
Further channels were examined over a broad range of 84F2 concentrations and a doseresponse curve was generated. The half-maximal inhibition concentration, or IC50 was
calculated (as described in the methods) and used as a quantitative measure of 84F2’s
potency.
Figure 4.2 shows the dose-response curve for 84F2 inhibition of purified RyR2 at the
single channel level. 84F2 was added at concentrations ranging from 1 nM to 100 µM
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for a total 12 channels. The pIC50 of 84F2 is 8.09 ± 0.139 (IC50 = 8.21 nM). Complete
inhibition of channel activity (Po < 1%) is seen at approximately 100 nM.
Concentrations of 84F2 up to 100 µM did not result in any return of RyR2 activity.
Following complete inhibition of the channel, addition of 1mM ATP (n=5), did not show
any increase in channel activity.
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Figure 4.1 Purified RyR2 Single Channel Traces in the Presence of 84F2
Representative single channel recordings of 84F2 tested on purified RyR2 reconstituted into
Proteoliopsomes. A) Control recording with 25 µM CaCl2 and no 84F2 present, Po = 0.97. B) Recording
after addition of 3 nM 84F2, Po = 0.43. C) Recording after the addition of 5 nM 84F2, Po = 0.28. D)
Recording after the addition of 35 nM 84F2, Po = 0.05. All traces are shown as two second sections of
recordings of at least two minutes. +36 mV was applied relative to the TRANS chamber indicating channel
openings upward as denoted by “o” in the plots.
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Figure 4.2 84F2 Inhibits Purified RyR2
84F2 inhibits purified RyR2 reconstituted into proteoliposomes from sheep cardiac muscle. Data is
normalized as the percent of the control, 25 µM calcium single channel recording. Each data point
represents 3-12 separate single channel recordings of at least two minutes. Fitting of the curve yields a
pIC50 = 8.09 ± 0.139 (± standard error), or IC50 = 8.21 nM.
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4.2

Effect of 84F2 on Purified RyR2 Dwell Times

84F2 single channel data was analyzed to better understand the mechanism by which
84F2 inhibits the gating of RyR2. Average closed and open dwell times were calculated
at each concentration of 84F2 tested and significance was calculated (as described in
the methods).
Figure 4.3 shows the average closed dwell time (Tc) of RyR2 over a range of 84F2
concentrations (1 nM to 100 nM). The general trend shows an increase in Tc as
concentrations are increased. Calculation of p-values reveal a significant increase in the
closed time over that of the control for concentrations indicated on the graph by “*”.
Figure 4.4 shows the average open time (To) of RyR2 for the same data set shown in
Figure 4.3. No significant decrease in the open time was seen at lower concentrations of
84F2. At higher concentrations of 84F2, To was decreased in a significant manner as
indicated by “*”.
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Figure 4.3 84F2 Increases the Closed Dwell Time of Purified RyR2
Calculation of the average closed dwell times of purified RyR2 incorporated into a planar lipid bilayer.
Data is normalized as the percent of the control Tc value, measured in the absence of 84F2. Each
concentration represents between 3-12 separate single channel recordings. Data which show a significant
increase in the closed dwell times compared to the control are indicated by “*.”
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Figure 4.4 84F2 Decreases the Open Dwell Time of Purified RyR2 at High
Concentrations
Calculation of the average open dwell times of purified RyR2 incorporated into a planar lipid bilayer. Data
is normalized as the percent of the control To value, measured in the absence of 84F2. Each concentration
represents between 3-12 separate single channel recordings. Data which show a significant increase in the
closed dwell times compared to the control are indicated by “*.”
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4.3

Ionic Strength Dependence of 84F2 Inhibition of Purified RyR2

84F2 was tested on purified RyR2 single channel activity at 400 mM KCl in a manner
identical to the experiments in section 4.1. Figure 4.5 shows the dose-response curve of
84F2 added to purified RyR2 at both 250 mM KCl (closed circles) and 400 mM KCl (open
triangles). 84F2 yields pIC50 values of 8.09 ± 0.14 and 7.12 ± 0.16 at 250 mM KCl and 400
mM KCl, respectively (IC50 = 8.13 nM and 75.8 nM).
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Figure 4.5 84F2 Inhibition of Purified RyR2 at Higher Ionic Strength
84F2 inhibition of purified RyR2 reconstituted into proteoliposomes. Data is normalized as the percent of
the control, 25 µM calcium single channel recording. As determined from the fit, 84F2 at 250 mM KCl
(closed circles) yields a pIC50 = 8.09 ± 0.14 (± standard error) (IC50 = 8.21 nM, n = 3-12). 84F2 at 400 mM
KCl (open triangles) yields a pIC50 = 7.12 ± 0.16 (± standard error) (IC50 = 75.6 nM, n = 3-8).
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4.4

Discussion: 84F2 Directly Inhibits RyR2

The inhibition of CaSPF in RyR2R176Q/+ cardiomyocytes, as well as the inhibition of VT in
RyR2R176Q/+ mice indicated that 84F2 was a potent inhibitor of arrhythmia resulting from
RyR2-dysfunction. 84F2 was designed to inhibit RyR2 and the inhibition in CaSPF
indicates that RyR2 was inhibited in the presence of 84F2. For these reasons, it is
believed that 84F2’s mechanism of treating arrhythmia is a direct inhibition of RyR2.
Here we have shown that purified RyR2 channels in a planar lipid bilayer were inhibited
in the presence 84F2, confirming that 84F2 can directly inhibit RyR2. Table 4.1
summarizes 84F2 potency in inhibiting RyR2. The similarity in the potency (IC50) of
inhibition, in the single channel and Ca2+ spark assays, suggests that 84F2’s inhibition of
CaSPF is due to direct inhibition of RyR2. Taken together, these results support the
hypothesis that 84F2’s mechanism at treating arrhythmia is through the direct inhibition
of 84F2.
Table 4.1 Summary of 84F2 Inhibition of RyR2
Assay
Single Channel (250 mM KCl)
Single Channel (400 mM KCl)
Ca2+ Sparks

IC50 (nM)
8.21
75.6
35.40

Single channel measurements made at 400 mM KCl indicated that 84F2 has a reduced
IC50 at higher ionic strengths. Increases in ionic strength can lead to shielding of charge
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groups, which can lead to weakened interactions. This results suggests the affinity for
RyR2 for 84F2 is dependent on a charge interaction.
84F2 inhibition was slightly greater at the single channel level (250 mM KCl) compared
to in the Ca2+ spark assay. IC50 values of 8.09 nM and 35.40 nM, respectively. These two
assays are quite different in nature and small discrepancies in results are expected.
However, it is very likely that local concentrations of 84F2 near RyR2 are different in
these two assays. In the single channel assay, 84F2 immediately sees the RyR2
cytoplasmic face. 84F2 in the spark assay, first must cross the sarcolemma before
interacting with RyR2. Some of the 84F2 may be cleaved, prior to, and after entering the
cell, thereby reducing concentrations of 84F2 around RyR2.
How a compound affects the gating of the channel is important in terms of its
usefulness in drug development. Decreasing the open time of the RyR2 results in
reduced Ca2+ transient, which can lead to reduced contractile force of muscles. An
increased closed time allows for more Ca2+ to be pumped into the SR during diastole,
preventing SR Ca2+ load from diminishing. For this reason, ideal compounds to treat
RyR2-dysfunction would inhibit RyR2 by increasing the closed time.
Analysis of the single channel dwell times in the presence of 84F2 revealed that
decreased Po results mainly from a significant increase of RyR2 closed time (Figure 4.3
and Figure 4.4). At high concentration of 84F2, the open time was also seen to be
significantly decreased.
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5

Results: Determination of the Active Metabolite of 84F2

84F2, can be rapidly cleaved at its ester linkage, in either the cell or in the extracellular
space. Results at the whole animal level showed that i.p. injection of 84F2 reproducibly
prevents the incidence of arrhythmia in RyR2R176Q/+ mice for up to 15 minutes after
injection. This could indicate that 84F2’s reduction in the incidence of VT may be
through some other mechanism, besides direct inhibition of RyR2.
This possibility seems remote given that 84F2 inhibits RyR2 at similar concentrations the
single channel and cellular level, which supported that 84F2’s mechanism is through
direct inhibition of RyR2. In addition, cellular data showed that 78F3 also inhibits CaSPF
from RyR2R176Q/+ mouse cardiomyocytes. This all seems to indicate that the cleavage of
84F2 results in a metabolite which may also inhibit RyR2 in a manner like 84F2.
Hypothesis 2: Following breakdown of 84F2, either metabolite of 84F2 may also inhibit
RyR2.
To test this hypothesis, we used purified RyR2 single channels in a planar lipid bilayer to
test the compounds, DEAE and 78F3, to determine if either inhibited RyR2 in a manner
similar to 84F2.
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5.1

2-(Diethylamino)ethanol (DEAE) Inhibition of Purified RyR2 at the Single Channel
Level

RyR2, purified and reconstituted into proteoliposomes as described in the methods, was
incorporated into an artificial bilayer and single channel activity was tested as a function
of DEAE concentration.
Figure 5.1 shows representative single channel recordings of purified RyR2 reconstituted
into proteoliposomes in the presence of DEAE and 250 mM KCl on both sides of the
bilayer. Trace A shows a control recording with no DEAE. This control recording yielded
an average open probability of 0.70. Subsequent recordings B, C, and D show channels
in the presence of 100 nM, 1 µM, and 10 µM DEAE which resulted in open probabilities
of 0.67, 0.77, and 0.76, respectively.
Further channels were looked at under identical conditions over a range of DEAE
concentrations and a dose-response curve was generated. Figure 5.2 shows the doseresponse curve for DEAE inhibition of purified RyR2 at the single channel level.
Concentrations of DEAE were added ranging from 10 nM to 10 µM and fit as described
in the methods. At no concentration of DEAE tested (up to 100 µM) was inhibition seen.
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Figure 5.1 Purified RyR2 Single Channel Traces in the Presence of DEAE
Representative single channel recordings of DEAE’s effect on purified RyR2 A) Control recording with 25
µM CaCl2 and no DEAE present, Po = 0.70. B) Recording after addition of 100 nM DEAE, Po = 0.67. C)
Recording after the addition of 1 µM DEAE, Po = 0.77. D) Recording after the addition 10 µM DEAE, Po =
0.76. All traces are shown as two second sections of recordings of at least two minutes. +36 mV was
applied relative to the TRANS chamber indicating channel openings upward as denoted by “o” in the
plots.
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Figure 5.2 DEAE Does Not Inhibit Purified RyR2
DEAE does not inhibit purified RyR2 reconstituted into proteoliposomes. Data is normalized as the
percent of the control, 25 µM calcium, single channel recording. Each data point represents 3-5 separate
single channel recordings of at least two minutes.
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5.2

78F3 Inhibition of Purified RyR2 at the Single Channel Level

RyR2, purified and reconstituted into proteoliposomes as described in the methods, was
incorporated into an artificial bilayer and single channel activity was tested as a function
of 78F3 concentration.
Figure 5.3 shows representative single channel recordings of purified RyR2 in the
presence of 78F3 and 250 mM KCl. Trace A shows a control recording with no 78F3, this
control recording yielded an average open probability of 0.98. Subsequent recordings B,
C, and D show channels in the presence of 10 nM, 35 nM, and 50 nM 78F3 result in open
probabilities of 0.78, 0.03, and 0.003, respectively. Subsequent recordings on this
channel at higher 78F3 concentrations completely inhibited all channel activity. 78F3 is
seen here to inhibit purified RyR2 in a concentration-dependent manner.
Further channels were looked at under identical conditions over a range of 78F3
concentrations and a dose-response curve was generated. Figure 5.4 shows the doseresponse curve for 78F3 inhibition of purified RyR2 at the single channel level.
Concentrations of 78F3 were added ranging from 1 nM to 100 µM and the doseresponse curve was fit as described in the methods. The pIC50 of 78F3 is 8.02 ± 0.10 (IC50
= 9.45 nM). Complete inhibition of the channel is seen at approximately 100 nM. The
addition of concentrations of 78F3 up to 100 µM resulted in no return of RyR2 activity.
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Figure 5.3 Purified RyR2 Single Channel Traces in the Presence of 78F3
Figure Representative single channel recordings of 78F3’s effect on purified RyR2. A) Control recording
with 25 µM CaCl2 and no 78F3 present, Po = 0.98. B) Recording after addition of 10 nM 78F3, Po = 0.78. C)
Recording after the addition of 35 nM 78F3, Po = 0.03. D) Recording after the addition of 50 nM 78F3, Po
= 0.003. All traces are shown as two second sections of recordings of at least two minutes. +36 mV was
applied relative to the TRANS chamber, indicating channel openings upward as denoted by “o” in the
plots.
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Figure 5.4 78F3 Inhibits Purified RyR2
78F3 inhibits purified RyR2 reconstituted into proteoliposomes. Data is normalized as the percent of the
control, 25 µM calcium, single channel recording. Each data point represents 3-12 separate single channel
recordings of at least two minutes. Determined from the fit, 78F3 yields a pIC50 = 8.02 ± 0.10 (± standard
error), IC50 = 9.45 nM.
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5.3

Discussion: Following Breakdown of 84F2, 78F3 Inhibits RyR2

The Ca2+-spark and whole animal data from RyR2R176Q/+ mice showed that 84F2 was
effective in reducing arrhythmogenic states. Results at the single channel level
supported the hypothesis that 84F2’s mechanism at treating arrhythmia is through
direct inhibition of RyR2. However, 84F2’s ester can be rapidly cleaved in-vivo making
the data at the whole animal level difficult to explain if our hypothesis is correct. This
contradiction might be explained if one of the metabolites, following the breakdown of
84F2 could also inhibit RyR2.
Figure 5.5 shows dose-response curves for 84F2, and its two metabolites following its
cleavage. 78F3 and 84F2 shared near identical dose-response curves, while DEAE
showed no inhibition of RyR2. The potency (IC50) of these three compounds is
summarized in Table 5.1. IC50 values for 84F2 and 78F3, were again nearly identical. This
data supports our hypothesis that one of 84F2’s metabolites, can also inhibit RyR2 in a
manner similar to 84F2.
Table 5.1 Summary of 84F2, 78F3, and DEAE Inhibition of Purified RyR2
Compound
84F2
78F3
DEAE

IC50 (nM)
8.21
9.45
No inhibition
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In the Ca2+-spark assay, 84F2 showed an IC50 = 35.40 nM, while 78F3 showed a reduced
IC50 = 200 nM. This does not reflect single channel data, which resulted in identical
potency of the two compounds.
The difference in potency in the Ca2+-spark assay may be explained by how each
compound enters the cell. 84F2’s ester allows it to readily cross the sarcolemma. 78F3,
likely does cross the membrane as easily, resulting in lower local concentrations near
RyR2.
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Figure 5.5 84F2, 78F3 and DEAE Inhibition of Purified RyR2
Dose-response curves for 84F2 and its two metabolites, 78F3 and DEAE. Compounds 84F2 (closed circles)
and 78F3 (open triangles) share near identical dose-responses, with overlapping pIC50 values, 8.09 ± 0.139
and 8.02 ± 0.10 (IC50 = 8.21 nM, 9.45 nM), respectively. DEAE (open squares) does not show any inhibition
of purified RyR2.

66

6

Results: Determination if 84F2 Inhibits RyR2 from Crude Cardiac SR

Arrhythmogenic states of RyR2R176Q/+ cells and RyR2R176Q/+ which were induced by
adrenergic stimulation, were diminished with treatment of 84F2. Normal ECC in these
assays was not affected following treatment with 84F2. This suggests that 84F2 may
only inhibit RyR2 following its dysfunction, which is known to occur following adrenergic
stimulation in CPVT. However, 84F2 was shown at the single channel level to inhibit
purified RyR2 in the absence of CPVT mutation or adrenergic stimulation. This suggests
an inherent similarity between the purified RyR2 and RyR2R176Q/+ that undergoes
adrenergic stimulation.
The literature suggests that the onset of arrhythmias in CPVT may be due to a
dissociation of key regulating proteins from RyR2 during adrenergic stimulation, leading
to a leak of Ca2+. In addition, the purification of RyR2 is known to remove associated
proteins. This may account for why 84F2 can inhibit the purified RyR2, while not
affecting normal ECC in RyR2R176Q/+ animals and cells.
Hypothesis 3: 84F2’s inhibition of RyR2 is dependent on the absence of key regulating
proteins.
To test this hypothesis, 84F2 was tested on RyR2 from crude cardiac SR which still
retains associated proteins.
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6.1

84F2 Single Channel Inhibition of RyR2 from Crude Cardiac SR

RyR2 from crude cardiac SR vesicles, were incorporated into an artificial bilayer and
single channel activity was tested as a function of 84F2 concentration. Figure 6.1 shows
representative single channel recordings of RyR2 from crude cardiac SR incorporated
into a planar bilayer in the presence of 84F2. Trace A shows a control recording with no
84F2, this control recording yielded an average open probability of 0.95. Subsequent
recordings B, C, and D show channels in the presence of 100 nM, 1 µM, and 10 µM 84F2
resulting in open probabilities of 0.82, 0.79, and 0.52, respectively. Concentrations
tested at 30 µM and 100 µM showed that complete inhibition of the channel was seen
only at a concentration of 100 µM.
Further channels were examined under identical conditions over a range of 84F2
concentrations and a dose-response curve was generated. Figure 6.2 shows the doseresponse curve for 84F2 inhibition of RyR2 from crude cardiac SR at the single channel
level. Concentrations of 84F2 ranging from 10 nM to 100 µM were added to the CIS
chamber and fit as described in the methods. The pIC50 of 84F2 tested on RyR2 from
crude cardiac SR is 5.09 ± 0.44 (IC50 = 8.11 µM). Complete inhibition of the channel was
seen at 100 µM on all channels tested at this concentration (n=4). Each data point on
the graph represents between 3 and 7 separate single channel recordings.
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Figure 6.1 Non-Purified RyR2 Single Channel Traces in the Presence of 84F2
Representative single channel recordings of RyR2 from crude cardiac SR in the presence of 84F2. A)
Control recording with 25 µM CaCl2 and no 84F2 present, Po = 0.95. B) Recording after addition of 100
nM 84F2, Po = 0.82. C) Recording after the addition of 1 µM 84F2, Po = 0.79. D) Recording after the
addition of 10 µM 84F2, Po = 0.52. All traces are shown as two second sections of recordings of at least
two minutes. +36 mV was applied relative to the TRANS chamber, indicating channel openings upward as
denoted by “o” in the plots.
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Figure 6.2 84F2 Shows Diminished Inhibition of RyR2 from Crude Cardiac SR
Inhibition of single channel activity on RyR2 from crude cardiac SR in the presence of 84F2. Data is
normalized as the percent of the control, 25 µM calcium, single channel recording. Each data point
represents 3-7 separate single channel recordings of at least two minutes. Fitting of the curve yields a
pIC50 = 5.09 ± 0.44 (± standard error), IC50 = 8.11 µM.
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6.2

84F2, 78F3, and DEAE Inhibition of Equilibrium 3H-Ryanodine Binding to RyR2
from Crude Cardiac SR

Equilibrium 3H-ryanodine binding to RyR2 from crude cardiac SR was measured in the
presence of 84F2, 78F3, and DEAE. This assay was carried out in the presence of 250
mM KCl, at 37°C for 3 hours (details described in methods).
Figure 6.3 shows how these compounds affect equilibrium binding. Both 84F2 and 78F3
showed very weak inhibition of ryanodine binding to RyR2 from crude cardiac SR, with
inhibition only occurring at concentrations greater than 10 µM. DEAE showed no
inhibition at concentrations as high as 100 µM.
Control binding measurements were made at the same time under identical conditions
in the absence of any compound. Control equilibrium binding reached a maximum value
1.3 pmol ryanodine / mg SR. Each concentration was repeated in triplicate, normalized
as the percent of the control, averaged and standard error was calculated.
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84F2 shows no inhibition of 3H-ryanodine binding to crude cardiac SR except at very high concentrations
(> 10 µM). 78F3 shows a similar inhibition to 84F2 and DEAE showed no inhibition at all concentrations
tested. Each bar of the graph represents measurements made in triplicate, normalized to the percentage
of control, ± standard error. Control equilibrium binding measured 1.3 pmol ryanodine / mg SR and was
normalized to 1.
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6.3

Rate of 3H-Ryanodine Binding in the Presence of 84F2

Figure 6.4 shows how 84F2 affects the rate of 3H-ryanodine binding to crude cardiac SR
vesicles. 84F2 was tested at concentrations of 0 µM (closed circles), 1 µM (open circles),
5 µM (closed triangles) and 10 µM (open triangles). The amount of 3H-ryanodine bound
was measured at 5, 10, 15, and 20 minutes and fit as described in the methods.
Results, as summarized in Table 6.1, show that 84F2 inhibits the rate of 3H-ryanodine
binding to crude cardiac SR in a concentration dependent manner. An estimate of the
concentration of half-maximal inhibition (using 15.53 as the maximal rate and 0 as the
minimal rate) yields an IC50 is between 1 µM and 5 µM 84F2.

Table 6.1 Summary of 84F2 Inhibition in the rate of 3H-Ryanodine Binding
Concentration 84F2 (µM)
0
1
5
10

Rate ± Standard Error
(fmol/mg/min)
15.5 ± 0.66
10.7 ± 2.02
6.8 ± 1.69
3.8 ± 0.48
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Y-Intercept ± Standard
Error (fmol/mg)
118.01 ± 9.05
132.43 ± 27.65
116.40 ± 23.09
116.33 ± 6.62

fmol Ryanodine Bound / mg SR

600
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1 µΜ 84F2
5 µM 84F2
10 µM 84F2
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Figure 6.4 84F2 Decreases the Rate of 3H-Ryanodine Binding to RyR2 from Crude
Cardiac SR
84F2 shows a moderate inhibition in the rate of 3H-ryanodine binding to RyR2 from crude cardiac SR.
Rates were determined as the slope of the linear fits. Control time points (closed circle) at 5, 10, 15 and 20
minutes yield the maximum rate of 15.5 fmol/mg/min ± 0.66fmol/mg/min. Identical time points were
used with 84F2 concentrations of 1 µM (open circles), 5 µM (closed triangles) and 10 µM (open triangles).
These concentrations yielded rates of 10.7 fmol/mg/min ± 2.02 fmol/mg/min, 6.8 fmol/mg/min ± 1.69
fmol/mg/min, 3.8 fmol/mg/min ± 0.48 fmol/mg/min, respectively. Each Data point is carried out in
triplicate and represents the mean ± standard error.
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6.4

Discussion: 84F2 has Reduced Inhibition of RyR2 from Crude Cardiac SR

84F2 has been shown to inhibit arrhythmogenic states resulting from RyR2-dysfunction
induced by adrenergic stimulation in a CPVT animal model. 84F2 had not effect on
normal ECC in these animals suggesting 84F2 only treated RyR2 in a dysfunctional state.
Our single channel results showed that 84F2 inhibited purified RyR2 at similar
concentrations to the inhibition of CaSPF in RyR2R176Q/+ cardiomyocytes. This suggested
that purified RyR2 has inherent similarities to RyR2R176Q/+ following adrenergic
stimulation.
Here we have shown that 84F2 Inhibition of RyR2 from crude cardiac SR was reduced
compared to inhibition seen on both the purified RyR2 single channels and CaSPF of
RyR2R176Q/+ myocytes. Results, as summarized in Table 6.2, support the hypothesis that
84F2 is more potent at inhibiting RyR2 in the absence of key regulating proteins.
Table 6.2 Summary of 84F2 Inhibition in the Presence of Associated Proteins
Assay
Single Channel

RyR2 Preparation
Purified

IC50 (nM)
8.21

CaSPF

RyR2R176Q/+

35.40

Single Channel

Crude Cardiac SR

8,110

Rate of 3H-Ryanodine
Binding
Equilibrium 3H-Ryanodine
Binding

Crude Cardiac SR

~1,000 – 5,000

Crude Cardiac SR

> 10,000
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The strongest evidence supporting this hypothesis is the large difference in single
channel results as shown in Figure 6.5. Figure 6.5 Comparison of Single Channel
Inhibition of RyR2 from Crude Cardiac SR and Purified RyR2 84F2 showed a reduction in
inhibition of RyR2 from crude cardiac SR compared to measurements carried out on
purified RyR2 under identical conditions. No overlap in inhibition can be seen at any
concentration of 84F2 and the half-maximal inhibition concentration increased
approximately 1,000 fold, from 8.21 nM to 8.11 µM, when tested on RyR2 from crude
cardiac SR. Inhibition in the rate of 3H-ryanodine binding is seen at concentrations
closely resembling concentrations seen with single channel results of RyR2 from crude
cardiac SR.
Equilibrium experiments had differing results, showing a greater reduction in inhibition
of RyR2 from crude cardiac SR by 84F2. Only concentrations > 10 µM of 84F2 were
effective in inhibiting binding of 3H-ryanodine and complete inhibition was not
achievable at concentrations as high as 100 µM.
The 3H-ryanodine binding results indicate that rates more closely reflect experiments
carried out at the single channel level. Numerous equilibrium 3H-ryanodine binding
experiments were carried out with 84F2 to try to characterize these differences,
however, under no conditions tested was 84F2 inhibition of 3H-ryanodine binding
altered (Data not shown in this work). Several compounds are known to inhibit RyR2
single channel activity while not inhibiting 3H-ryanodine binding, but the cause remains
unknown.
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One interesting result from the equilibrium experiments was that, like in the single
channel studies, 84F2 and 78F3 shared similar inhibition concentrations of 3H-ryanodine
equilibrium binding, while DEAE showed no inhibition. This is further evidence that 78F3
can also inhibit RyR2 following the breakdown of 84F2.
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Figure 6.5 Comparison of Single Channel Inhibition of RyR2 from Crude Cardiac
SR and Purified RyR2 in the Presence of 84F2
Dose-response curves for 84F2 inhibition of purified RyR2 (black circles) and non-purified RyR2 (grey
circles). 84F2 shows clear differences in its strength of inhibition of purified and non-purified RyR2,
yielding IC50 values of 8.13 nM and 8.11 µM, respectively.
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7

Results: Determination of Calmodulin’s Role in 84F2’s Inhibition of RyR2

The ability of 84F2 to treat arrhythmogenic states in CPVT animals, while not affecting
normal ECC, was hypothesized to be due to 84F2 only inhibiting RyR2 in a dysfunctional
state. In support of this hypothesis, 84F2 was a significantly less potent inhibitor of RyR2
in crude cardiac SR (in the presence of associated proteins) than in our purified
preparation.
Particularly interesting is the similarity between the concentrations of 84F2 that inhibit
the purified RyR2 at the single channel level, and inhibit CaSpF in RyR2R176Q/+
cardiomyocytes. This indicates that the purified RyR2 is in a conformation similar to
dysfunctional RyR2 which arises from adrenergic stimulation of CPVT cells.
Evidence in the literature suggests that RyR2-dysfunction in CPVT is due to a dissociation
of CaM from RyR2 during adrenergic stimulation83,84,85. CaM is also known to be absent
from RyR2 following the purification protocols we follow.
Hypothesis 4: Inhibition of RyR2 by 84F2 is dependent on CaM dissociation from RyR2.
To test this hypothesis, we compared the sensitivity of the purified RyR2 at the single
level to inhibition by 84F2 in the absence and presence of CaM.
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7.1

Inhibition of Purified RyR2 Single Channel Activity by 84F2 in the Presence of
Calmodulin

Inhibition of purified RyR2 by 84F2 was measured in a manner identical to the
experiments in Chapter 4, with CaM added to the CIS chamber prior to the addition of
84F2. Following the addition CaM, increasing concentrations of 84F2 were added to the
CIS chamber and single channel activity was recorded.
Figure 7.1 shows the dose-response curve for 84F2 inhibition of RyR2 in the presence of
either 100 nM CaM (open circles), or 1 µM CaM (closed circles). 84F2 has nearly an
identical dose-response curve at both concentrations of CaM. 84F2 in the presence of 1
µM CaM resulted in a pIC50 = 5.75 ± 0.39 (IC50 = 1.77 µM). 84F2 in the presence of
100nM CaM resulted in a pIC50 = 5.73 ± 0.29 (IC50 = 1.86 µM).
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Figure 7.1 Inhibition of Purified RyR2 by 84F2 in the Presence of Calmodulin
84F2 has a reduced inhibition of purified RyR2 in the presence of calmodulin. Each data point normalized
as the percent of the control 100 nM (grey circles) or 1 µM (open circles) calmodulin recording. Each data
point represents 3-9 separate single channel recordings of at least two minutes. Fitting of the curve for
84F2 in the presence of 1 µM CaM yields a pIC50 = 5.75 ± 0.39 (± standard error), IC50 = 1.77 µM, n = 3-9.
84F2 in the presence of 100nM CaM yields a pIC50 = 5.73 ± 0.29 (±standard error), IC50 = 1.86 µM, n = 3-9.
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7.2

Calmodulin Inhibition of RyR2

In addition to 84F2’s inhibition of RyR2, CaM is also known to modulate channel activity.
Single channel measurements of Po were examined prior to, and following, the addition
of CaM in both the purified RyR2 and RyR2 from crude cardiac SR.
Table 7.1 summarizes CaM’s effect on RyR2 Po. Data shows similar inhibition of purified
RyR2 at both concentrations of CaM tested, with Po values decreasing to approximately
80% of control values. CaM showed no inhibition of RyR2 from crude cardiac SR channel
activity.
Table 7.1 Calmodulin Inhibition of RyR2
RyR2 Type

CaM (µM)

Control Po

CaM Addition Po

n

Purified
Purified
Non-Purified

0.1
1
1

0.96 ± 0.17
0.98 ± 0.04
0.72 ± 0.05

0.79 ± 0.12
0.80 ± 0.09
0.76 ± 0.14

9
9
4
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7.3

UV-Vis Spectrum of 84F2 and CaM

84F2 and CaM’s UV-Vis spectrums were examined to determine if interactions between
CaM and 84F2 may exist.
Figure 7.2 shows the resulting UV-Vis spectrums of 84F2, CaM, as well as the
combination of CaM and 84F2. A concentration of 1 µM CaM and was used to mimic the
concentration used in single channel studies. CaM shows a strong absorption peak at
~220 nm. 3 µM 84F2 resulted in a similarly sized absorption peak at ~315 nm. These two
individual absorption spectrums were added together and plotted as the “calculated
sum,” shown on the graph. Absorption measurements made in the presence of both 3
µM 84F2 and 1 µM CaM resulted in an identical absorption spectrum as the calculated
sum.
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Figure 7.2 UV-Vis Spectrums of 84F2 and Calmodulin
Absorption spectrum measurements made in the presence of 84F2 and CaM. 1 µM CaM resulted in an
absorption peak at 220 nm. 3 µM 84F2 resulted in an absorption peak at 315 nm. Individual spectrum
measurements for the CaM and 84F2 were combined and plotted as the “calculated sum.” Absorption
measurements made in the presence of both CaM and 84F2 resulted in an identical spectrum to that of
the “calculated sum.”
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7.4

Discussion: CaM Reduces 84F2’s Potency in Inhibiting Purified RyR2

Data from the RyR2R176Q/+ mouse model suggested that 84F2 only inhibits a
dysfunctional RyR2. Our single channel results supported this and indicate that this
dysfunction is due to the absence of key regulatory proteins. These results along with
the evidence in the literature all pointed towards CaM dissociation as a key factor in the
ability of 84F2 to inhibit RyR2 channel activity.
This hypothesis, which states that the absence of CaM is responsible for differences in
84F2’s potency, was dependent on the presence, or absence, of CaM in our different
RyR2 preparations used at the single channel level. The literature suggests that our
preparation of purified RyR2 does not contain CaM. However, the presence of CaM in
cardiac SR preparation in the bilayer is less certain. To test whether CaM was present in
our two preparations, CaM modulation of single channel activity was measured.
CaM is known to modulate the activity of RyR2, acting as an inhibitor in its Ca2+-bound
form (Ca2+ > 1 µM). Therefore, RyR2 activity at the single channel level following the
addition of CaM to the cytoplasmic solution (Ca2+ = 25 µM), should indicate the
presence or absence of native CaM.
Data, which is shown in Table 7.1, indicates a reduction in Po with the addition of CaM
to purified RyR2. This 20% reduction in Po agrees with values in the literature for CaCaM
inhibition of purified RyR2. The identical reduction in Po at both concentrations of CaM
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indicate that 100 nM CaM is sufficient in saturating RyR2 binding sites. This is in strong
support of the literature evidence that CaM is not present in our purified RyR2.
RyR2 from crude cardiac SR did not show a reduction in Po with the addition of
saturating levels of CaM. In addition, control activity measurements of RyR2 from crude
cardiac SR (Po = 0.72) were lower than those for the purified RyR2 (Po = 0.98). RyR2
from crude cardiac SR control activity more closely resembled activity of purified RyR2 in
the presence of CaM (Po = 0.80). This indicates that CaM is likely still present in RyR2
from crude cardiac SR added to the bilayer.
The next question was whether the presence of CaM would decrease the inhibition of
purified RyR2 by 84F2. Figure 7.3 shows the dose-response curves for 84F2 inhibition of
purified RyR2 under identical conditions, with (grey circles) and without (black circles) 1
µM CaM present. The addition of 1 µM CaM strongly reduced 84F2’s potency. No
overlap in the curves at any concentration of 84F2 was observed until RyR2 was
completely inhibited. The resulting half-maximal inhibition concentration increased
from 8.13 nM to 1.77 µM with the addition of CaM. This result is in support of our
hypothesis that CaM-dissociation from RyR2 is a key factor in 84F2’s mechanism of
inhibition.
One mechanism that could have accounted for this reduced inhibition of RyR2 by 84F2,
was an interaction between CaM and 84F2. The resulting in a CaM-84F2 complex may
prevent 84F2 from inhibiting RyR2, effectively decreasing its potency. UV-Vis
measurements (Figure 7.2) indicated no changes in absorption peaks for the CaM and
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84F2 when combined. This result indicated that no obvious interaction between the two
existed, but did not rule out possible interactions that may not affect the absorption
spectrums. However, the results showing that 84F2’s dose-response was nearly identical
at 10-fold differences in CaM (Figure 7.1) indicates that a CaM-84F2 interaction is a
highly unlikely as the mechanism of reduced inhibition of RyR2.
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Figure 7.3 Calmodulin Decreases Inhibition of Purified RyR2 by 84F2
Dose-response curves for 84F2 inhibition of purified RyR2 purified RyR2 with (grey circles) and without
(black circles) the addition of 1 µM CaM. 84F2 a clear reduction in its strength of inhibition of purified
RyR2 in the presence of 1 µM CaM present. 84F2 in the absence of CaM resulted in an IC50 = 8.13 nM.
84F2 with the addition of 1 µM CaM resulted in an IC50 = 1.77 µM.
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8

Conclusions and Model of 84F2’s Mechanism

Cardiac disorders resulting in improper Ca2+-cycling in cardiomyocytes can lead to life
threatening conditions. Ca2+ leak from SR arises because of RyR2-dysfunction associated
with these disorders. CPVT, is one such disorder in which mutations in RyR2 lead to its
dysfunction during adrenergic stimulation. How adrenergic stimulation in CPVT leads to
RyR2-dysfunction remains unclear. The literature suggests that phosphorylation of RyR2,
during adrenergic stimulation, results in dissociation of key regulatory proteins86.
Here we have introduced a novel compound, 84F2, designed to inhibit RyR2-Ca2+ leak.
Using a CPVT mouse model, RyR2R176Q/+, we have shown 84F2 to be effective in treating
arrhythmogenic states that result from adrenergic stimulation, while not altering normal
ECC. These are two ideal characteristics of a drug used to treat arrhythmias.
In addition to showing 84F2’s efficacy in treating arrhythmia, we have investigated the
underlying mechanisms involved in how 84F2 inhibits RyR2. The following key results
were shown:
84F2 treats arrhythmia through direct RyR2 Inhibition. (Chapter 4)
Following breakdown of 84F2, 78F3 can also inhibit RyR2 (Chapter 5). This is supported by
data showing that 78F3 inhibits single channel activity and CaSPF in cells derived from a CPVT
mouse model.
84F2’s inhibition of RyR2 is dependent on the absence of key regulating proteins. (Chapter 6)
Inhibition of RyR2 by 84F2 is dependent on CaM-dissociation from RyR2. (Chapter 7)
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These findings supported the hypothesis in the literature which suggests that
dissociation of regulatory proteins during adrenergic stimulation is the underlying
mechanism of RyR2-dysfunction. We have further shown that the addition of one of
these proteins, CaM, can prevent 84F2 from inhibiting purified RyR2.
Figure 8.1 shows three dose-response curves for 84F2 inhibition of: purified RyR2 (black
circles), RyR2 from crude cardiac SR (open circles), and purified RyR2 with 1 µM CaM
(grey circles). The RyR2 from crude cardiac SR is only inhibited at high concentrations of
84F2. Purified RyR2 was potently inhibited by 84F2 at similar concentrations as those
seen in the CPVT model. The addition of 1 µM CaM to the purified RyR2, shifted 84F2’s
inhibition to concentrations like those seen in RyR2 from crude cardiac SR.
These results, as summarized in Table 8.1, support the theory that CaM-dissociation is
an underlying cause of RyR2-dysfunction in CPVT.
Table 8.1 Summary of 84F2 Inhibition of RyR2
Assay
Single Channel

RyR2
Purified

IC50 (nM)
8.21

CaSPF

RyR2R176Q/+

35.40

Single Channel

Crude Cardiac SR

8,110

Single Channel

Purified + 1 µM CaM

1,770
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Figure 8.1 Comparison of RyR2 Single Channel Activity by 84F2
84F2 showed weak inhibition of RyR2 from crude cardiac SR (Open Circles). 84F2 potently inhibited
purified RyR2 (black circles). Addition of 1 µM CaM decreased 84F2’s inhibition of purified RyR2 (grey
circles). All experiments carried out under identical conditions, as described in the methods.

91

3

Based on our findings we propose the following model, underlying the mechanism of
RyR2R176q/+ arrhythmia and 84F2’s targeted treatment.
Adrenergic stimulation of RyR2R176Q/+ cells results in the dissociation of CaM.
RyR2R176Q/+, deficient in CaM, becomes leaky to Ca2+, which leads to arrhythmias.
84F2 then binds to, and stabilizes the receptor, decreases the Ca2+ leak, and arrhythmias.
In the absence of adrenergic stimulation, RyR2R176Q/+ is still associated with CaM.
CaM stabilizes RyR2 and prevents 84F2 from inhibiting ECC.
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Figure 8.2 Model of 84F2 Inhibition of Arrhythmia resulting from RyR2R176Q/+
A) RyR2R176Q/+ loses their associated CaM following adrenergic stimulation. This can lead to arrhythmia. B)
84F2 stabilizes RyR2R176Q/+ following the dissociation of CaM. This diminishes the arrhythmia.
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